If you’ve been told you have a KRAS mutation — or another so-called “undruggable” cancer gene — you may have been placed on a specialty inhibitor designed to slow the disease. And these drugs can be helpful. But there’s a critical truth most patients are never told:

Most targeted cancer drugs are cytostatic, not cytotoxic.
They slow cancer down — they don’t eliminate it.

In this episode of Outsmart Cancer, Dr. Dino Prato explains why drugs targeting KRAS, BRAF, EGFR, MET, HER2, and similar pathways often create a temporary “honeymoon period.” Like unplugging a Christmas tree, the tumors dim — but once the drug stops working, the cancer lights back up.

The key question becomes: What are you doing with the time these drugs buy you?

Dr. Prato walks through how precision oncology uses that window to activate the immune system. By combining full DNA sequencing, RNA transcriptomics, immune spatial biology, and deep pathway mapping, doctors can identify thousands of targets — not just one mutation. This allows precision combinations, off-label strategies, phytotherapeutics, and direct-to-tumor immunotherapy delivery to expose cancer antigens, release DAMPS, and train natural killer and dendritic cells to eliminate disease system-wide.

Instead of waiting for resistance, this approach turns cytostatic slowdown into cytotoxic immune control, even in patients labeled MSS or “not candidates” for standard immunotherapy.

🎯 What You’ll Learn in This Episode:
• Why KRAS and similar inhibitors slow cancer but rarely eliminate it
• The difference between cytostatic and cytotoxic cancer treatment
• Why specialty drugs create a critical treatment window
• How RNA transcriptomics reveals escape pathways beyond DNA mutations
• Why immune spatial biology is essential for durable response
• How direct-to-tumor delivery protects immunity and increases effectiveness
• Why PD-1 inhibitors alone are rarely enough
• The right questions to ask when your targeted drug stops working

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493